120 results
Page 2 of 6
8-K
EX-99.1
5vkdrc6y9m05
13 Nov 23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
5:10pm
8-K
EX-99.1
rxvlwgfmychmd1u
3 Oct 23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
5:00pm
8-K
EX-99.1
f64ou55g
14 Aug 23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:30pm
8-K
EX-99.1
vvplpeumwzixf3ec
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
424B5
m0nmwflc
31 Jul 23
Prospectus supplement for primary offering
8:23am
8-K
EX-99.1
wvw yt236brq8c
27 Jul 23
55% objective response rate; 23% complete response rate in locally advanced cSCC
7:30am
424B5
gdyk qfi9nvwa
24 May 23
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
r2amd 5nvqrke4n7qr
24 May 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
5:24pm
8-K
EX-99.1
s6zp 3blr
15 May 23
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
4:21pm
8-K
EX-99.1
pnw7b0z 2x
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
424B5
bm3ujqj1brs90l
4 Apr 23
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
gzqxxx kv8xuz2sc
31 Mar 23
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
6:00am
8-K
EX-99.1
p7d7ppft9h
16 Dec 22
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7:05am
424B5
cv5m8
16 Dec 22
Prospectus supplement for primary offering
7:00am
8-K
EX-99.1
1r8xwsfkn8yzxtmz60
5 Dec 22
Checkpoint Therapeutics Announces Reverse Stock Split
4:45pm